CA2144155A1 - Ibuprofen-h2 antagonist combinations - Google Patents

Ibuprofen-h2 antagonist combinations

Info

Publication number
CA2144155A1
CA2144155A1 CA002144155A CA2144155A CA2144155A1 CA 2144155 A1 CA2144155 A1 CA 2144155A1 CA 002144155 A CA002144155 A CA 002144155A CA 2144155 A CA2144155 A CA 2144155A CA 2144155 A1 CA2144155 A1 CA 2144155A1
Authority
CA
Canada
Prior art keywords
ibuprofen
lysine
salt
famotidine
analgesically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002144155A
Other languages
English (en)
French (fr)
Inventor
Robert T. Sims
Robert Mcmahon
William Slivka
Thomas N. Gates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Johnson and Johnson Consumer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2144155A1 publication Critical patent/CA2144155A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002144155A 1992-09-29 1993-09-21 Ibuprofen-h2 antagonist combinations Abandoned CA2144155A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95344092A 1992-09-29 1992-09-29
US953,440 1992-09-29

Publications (1)

Publication Number Publication Date
CA2144155A1 true CA2144155A1 (en) 1994-04-14

Family

ID=25493996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002144155A Abandoned CA2144155A1 (en) 1992-09-29 1993-09-21 Ibuprofen-h2 antagonist combinations

Country Status (6)

Country Link
EP (1) EP0663839A4 (de)
JP (1) JPH08502254A (de)
AU (1) AU4931693A (de)
CA (1) CA2144155A1 (de)
MX (1) MX9306006A (de)
WO (1) WO1994007541A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349575A1 (en) 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4756823B2 (ja) 2001-06-01 2011-08-24 ポーゼン インコーポレイテッド Ｎｓａｉｄを協調的に送達するための薬剤組成物
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1919288A4 (de) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc Famotidin- und ibuprofenhaltige arzneimittel und ihre verabreichung
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
ATE539747T1 (de) * 2006-07-18 2012-01-15 Horizon Therapeutics Inc Verfahren und medikamente zur verabreichung von ibuprofen
NZ587202A (en) 2008-01-04 2013-03-28 Schabar Res Associates Llc Methods for measuring a patient response upon administration of a drug and compositions thereof
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2015163832A1 (en) * 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US4994604A (en) * 1990-01-10 1991-02-19 Merck & Co., Inc. Formation and resolution of ibuprofen lysinate
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC

Also Published As

Publication number Publication date
EP0663839A1 (de) 1995-07-26
JPH08502254A (ja) 1996-03-12
AU4931693A (en) 1994-04-26
WO1994007541A1 (en) 1994-04-14
EP0663839A4 (de) 1998-06-03
MX9306006A (es) 1995-01-31

Similar Documents

Publication Publication Date Title
CA2144155A1 (en) Ibuprofen-h2 antagonist combinations
US4571400A (en) Dihydrocodeine/ibuprofen pharmaceutical compositions and method
HU225887B1 (en) Process for producing pharmaceutical compositions containing flurbiprofen having painkiller activity
US4587252A (en) Hydrocodone/ibuprofen pharmaceutical compositions and method
EP0259990A1 (de) Schnell wirkende Mischung von Natrium-Sulindac und einer Base
JPH08505133A (ja) 解熱方法および鎮痛方法並びに光学的に純粋なｒ−ケトロラックを含む組成物
JPH03206064A (ja) 速効性かつ鎮痛効果が増強された鎮痛剤としてのｓ（＋）―イブプロフエン―ｌ―アミノ酸とｓ（＋）―イブプロフエン―ｄ―アミノ酸
CA2527368A1 (en) Pharmaceutical composition
US5288507A (en) Ibuprofen antacid combinations
CA2113916C (en) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent
AU642309B2 (en) Complexes containing S(+) phenyl alkane acids and amino sugars
WO1994003209A1 (en) Dexibuprofen/antacid/simethicone combinations
EP0707484A1 (de) Kombinationen aus h2-antagonist, alginat und antazidum
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
CA2144152A1 (en) Ibuprofen-caffine combinations
CA2215160A1 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
US4970202A (en) Pharmaceutical compositions containing non-steroidal anti-inflammatory drugs
EP0551180B1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria
CA1124648A (en) Anti-inflammatory combination having reduced ulcerogenicity
WO1995001792A1 (en) H2 antagonist-antihistamine combinations
JP2000026313A (ja) 消化管運動抑制剤
AU695642B2 (en) A novel antispasmodic and antinflammatory composition and a process for the manufacture thereof
JP2004002454A (ja) 消化管運動抑制剤
CA2684171C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
WO1995001784A1 (en) H2 antagonist-sucralfate-antiflatulent combinations

Legal Events

Date Code Title Description
FZDE Dead